GlassScriptPhysician profile
Maria E Faget
NPI 1932307527
$8,276.63
in general payments reported to CMS, 2019-2025
14 companies · $7,738 in 2025
The $7,738 reported for 2025 was more than what 98% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10.91 · 2020: $23.50 · 2022: $393 · 2024: $112 · 2025: $7,738.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $6,000 · Travel and Lodging: $1,548 · Food and Beverage: $302.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $6,000.00 |
| Travel and Lodging | $1,547.89 |
| Food and Beverage | $301.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $7,564.88 | 2025 | |
| Medical Device Business Services, INC. | $392.67 | 2022 | |
| Exeltis, USA INC. | $61.50 | 2024-2025 | Slynd |
| Pfizer INC. | $48.98 | 2025 | |
| Coopersurgical, INC. | $32.52 | 2024 | Endosee, Paragard T 380a |
| Mayne Pharma Commercial LLC | $28.37 | 2024 | |
| Daiichi Sankyo INC. | $23.50 | 2020 | |
| Biogen, INC. | $23.14 | 2025 | Zurzuvae |
| Novo Nordisk INC | $22.50 | 2024 | Wegovy, Saxenda |
| Boston Scientific Corporation | $20.27 | 2025 | Axonics |
| Astellas Pharma US INC | $19.28 | 2025 | Veozah |
| Amgen INC. | $14.32 | 2025 | Evenity |
| Hologic Sales and Service, LLC | $13.79 | 2024 | Aptima, Thinprep 2000 Processor |
| Duchesnay USA Incorporated | $10.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Faget listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.